Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabergoline Treatment Outcome by Target Prolactin Levels in Prolactinoma
NCT03457389Unknown
- Sponsor
- Seoul National University Hospital
- Start
- Feb 2018
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of cabergoline in prolactinoma (2 arms), sponsored by Seoul National University Hospital. Primary endpoint: Recurrence rate within 1 year after cabergoline withdrawal. Status: unknown.
02
Drugs
cabergoline
03
Conditions
prolactinoma
Beyond the preview
Go deeper on NCT03457389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03457389.